| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
(Papain-like protease (PLpro)(IC50 = 2.6 µM);SARS-CoV-2 PLpro(IC50 = 5.0 µM);SARS-CoV-2 PLpro(EC50= 21.0 µM)
SARS-CoV papain-like protease (PLpro) – IC50 = 2.6 ± 0.1 μM for (R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide. [1] SARS-CoV-2 papain-like protease (PLpro) – IC50 = 5.0 μM for (R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide. [2] |
|---|---|
| ln Vitro |
Strongly inhibiting the papain-like protease (PLpro) produced by the coronavirus that causes severe acute respiratory syndrome (SARS-CoV) is PLpro inhibitor. The IC50 value of PLpro inhibitor was determined to be 2.6 μM. With EC50 values of 13.1 μM, the PLpro inhibitor exhibits strong antiviral activity and is safe at the highest tested concentration. Notably, the in vitro inhibition of PLpro correlates with increasing antiviral potency, indicating that the compounds act directly on the enzyme in cells[1][2].
(R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (compound 6) inhibited SARS-CoV PLpro with an IC50 of 2.6 ± 0.1 μM. The addition of an NHAc group at the R3 position of the ortho-methyl benzene ring had little effect on IC50 compared to the corresponding amino compound. [1] (R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide inhibited SARS-CoV-2 PLpro activity with an IC50 of 5.0 μM using peptide-AMC substrate (50 μM). It also exhibited antiviral activity against SARS-CoV-2 (USA-WA1/2020 isolate) in Vero E6 cells with an EC50 of 21.0 μM. No cytotoxicity was observed at the concentrations tested. [2] |
| ln Vivo |
(R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide exhibited antiviral activity against SARS-CoV-2 (USA-WA1/2020 isolate) in Vero E6 cells with an EC50 of 21.0 μM. No cytotoxicity was observed at the concentrations tested. [2]
|
| Enzyme Assay |
For SARS-CoV-2 PLpro, IC50 assays used 100 nM enzyme, 50 μM peptide-AMC, in 98% assay buffer (100 mM NaCl, 50 mM Hepes pH 7.5, 0.01 mg/ml BSA, 5 mM DTT) with 2% DMSO, and inhibitor concentrations ranging from 1.25 μM to 20 μM or up to 100 μM depending on the compound. Fluorescence of AMC cleavage was measured. IC50 calculations were performed using Prism8. [2]
In the earlier study, IC50 measurements for SARS-CoV PLpro were performed by hand in duplicate in 96-well format using 50 μM RLRGG-AMC substrate, 2% DMSO, and varying inhibitor concentrations (0–200 μM). Reaction progress was monitored continuously (excitation 360 nm, emission 460 nm). Data were fitted to νi = ν0/(1+[I]/IC50). [1] |
| Cell Assay |
For SARS-CoV-2, Vero E6 cells were plated at 3 × 10⁵ cells/well in 12-well plates, infected with 8,000 PFU/well of SARS-CoV-2 (USA-WA1/2020 isolate) in the presence of (R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide at concentrations of 15, 30, 45, 65, and 80 μM, and incubated for 66 h at 37 °C with 5% CO2. Cells were fixed and stained with crystal violet to determine plaque numbers. EC50 was calculated using Prism8. Cytotoxicity was assessed using a bioassay (Lonza Toxilight) in Vero E6 cells treated with compound for 72 h. [2]
|
| Toxicity/Toxicokinetics |
(R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide showed no cytotoxicity in Vero E6 cells at concentrations up to 80 μM (the highest tested) as assessed by a cytotoxicity bioassay. [2]
|
| References |
|
| Additional Infomation |
KOM70144 is a benzamide compound, a derivative of GRL-0617, in which a hydrogen atom on the primary amino group is replaced by an acetyl group. It inhibits the papain-like protease (PLpro) of SARS-CoV and SARS-CoV-2, with IC50 values of 2.6 μM and 5.0 μM, respectively. Furthermore, it inhibits the infection of Vero E6 cells by SARS-CoV and SARS-CoV-2 in vitro (EC50 values of 13.1 μM and 21 μM, respectively). It exhibits dual activity as a protease inhibitor and an anticoronavirus drug. KOM70144 belongs to the naphthalene, benzamide, secondary carboxamide, and acetamide classes. Its function is related to that of GRL-0617.
(R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide (compound 6) is a naphthalene-based noncovalent PLpro inhibitor. In the synthetic optimization series, addition of an NHAc group at the R3 position of the ortho-methyl benzene ring (compared to the amino analogue GRL0617) resulted in little change in IC50 against SARS-CoV PLpro (2.6 μM vs. 0.6 μM for GRL0617). [1] For SARS-CoV-2, it was one of the compounds tested alongside GRL0617 and showed moderate inhibition of PLpro and antiviral activity. [2] |
| Molecular Formula |
C22H22N2O2
|
|---|---|
| Molecular Weight |
346.42228
|
| Exact Mass |
346.168
|
| Elemental Analysis |
C, 76.28; H, 6.40; N, 8.09; O, 9.24
|
| CAS # |
1093070-14-4
|
| PubChem CID |
44235889
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.303
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
506
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(C1=CC(NC(C)=O)=CC=C1C)N[C@H](C)C2=C(C=CC=C3)C3=CC=C2
|
| InChi Key |
KGPYBLOBHQLIET-OAHLLOKOSA-N
|
| InChi Code |
InChI=1S/C22H22N2O2/c1-14-11-12-18(24-16(3)25)13-21(14)22(26)23-15(2)19-10-6-8-17-7-4-5-9-20(17)19/h4-13,15H,1-3H3,(H,23,26)(H,24,25)/t15-/m1/s1
|
| Chemical Name |
(R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide
|
| Synonyms |
PLpro inhibitor, KOM70144; KOM-70144; KOM 70144;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 69~100 mg/mL ( 199.18~288.67 mM )
Ethanol : ~35 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8867 mL | 14.4333 mL | 28.8667 mL | |
| 5 mM | 0.5773 mL | 2.8867 mL | 5.7733 mL | |
| 10 mM | 0.2887 mL | 1.4433 mL | 2.8867 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
